Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina

Am Heart J. 2005 Nov;150(5):1007-14. doi: 10.1016/j.ahj.2004.12.008.

Abstract

Background: This study was performed to assess the relationship between oxidized low-density lipoprotein (OxLDL) and restenosis. OxLDL induces up-regulation of inflammatory genes and cytokines and recruits monocytes to the vessel wall. Elevated levels of monocytes post-percutaneous coronary intervention (PCI) are associated with in-stent restenosis.

Methods and results: One hundred forty-one patients with stable angina pectoris had serial blood samples drawn before PCI (68% balloon only, 32% stent), immediately post-PCI and at 6 and 24 hours, 3 days, 1 week, and 1, 3, and 6 months. Plasma levels of OxLDL-E06, a measure of oxidized phospholipid (OxPL) content on apoB-100 detected by antibody E06 (OxPL/apoB), autoantibodies to malondialdehyde-LDL and copper-oxidized LDL, and apoB-immune complexes were measured in all samples. Quantitative and qualitative coronary angiography was performed with 94% angiographic follow-up. Restenosis was defined as >50% diameter stenosis (%DS). The overall angiographic restenosis rate was 32% (39% in balloon group, 16% in stent group). OxPL/apoB levels rose significantly and OxLDL autoantibody titers decreased immediately post-PCI in patients both with and without restenosis, but there were no significant differences among groups. There was also no relationship of any OxLDL marker to lesion length, %DS, or minimal lumen diameter. No differences were noted in stent versus balloon-treated patients.

Conclusions: Serial measurement of a comprehensive panel of circulating OxLDL markers after uncomplicated PCI for stable angina does not predict restenosis.

MeSH terms

  • Angina Pectoris / blood
  • Angina Pectoris / therapy
  • Angioplasty, Balloon, Coronary*
  • Coronary Angiography*
  • Coronary Restenosis / blood*
  • Coronary Restenosis / diagnostic imaging*
  • Coronary Restenosis / therapy
  • Female
  • Humans
  • Lipoproteins, LDL / metabolism*
  • Male
  • Middle Aged

Substances

  • Lipoproteins, LDL